文献速递外周动脉疾病

紫杉醇涂层球囊治疗下肢动脉后大截肢风险的系统综述与荟萃分析

Editor's Choice - Risk of Major Amputation Following Application of Paclitaxel Coated Balloons in the Lower Limb Arteries: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.
PubMed 文献 · Eur J Vasc Endovasc Surg · 2021-07-27

OBJECTIVE: There have been concerns about the long term safety of paclitaxel coated devices in the lower limbs. A formal systematic review and meta-analysis of randomised controlled trials (RCTs) was performed to examine the long term risk of major amputation using paclitaxel coa…

要点

  • 紫杉醇涂层球囊组大截肢风险显著增加,HR 1.66(95%CI 1.14-2.42)。
  • 股腘动脉与膝下动脉风险一致,临界跛行患者需损害人数为35。

核心结论

  • 使用紫杉醇涂层球囊治疗外周动脉疾病后大截肢风险似乎增加,需紧急进一步研究。

主要发现

  • 预测区间95%CI 1.10-2.46(两阶段模型)。
  • 严重肢体缺血的需损害人数为35。

关键数值与推荐

  • 预测区间95%CI 1.10-2.46。
  • 严重肢体缺血需损害人数35。
  • 证据确定性因部分研究事件稀疏从高降为中。

临床怎么用

  • 临床使用紫杉醇涂层球囊治疗下肢动脉疾病时需警惕大截肢风险,尤其严重肢体缺血患者。
  • 应权衡紫杉醇涂层球囊的获益与潜在截肢风险,并考虑累积剂量。

局限性

  • 部分研究事件稀疏,证据确定性从高降为中。
  • 无发表偏倚证据,但中位随访仅两年。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: There have been concerns about the long term safety of paclitaxel coated devices in the lower limbs. A formal systematic review and meta-analysis of randomised controlled trials (RCTs) was performed to examine the long term risk of major amputation using paclitaxel coated balloons in peripheral arterial disease (PAD). METHOD: This systematic review was registered with PROSPERO (ID 227761). A broad bibliographic search was performed for RCTs investigating paclitaxel coated balloons in the peripheral arteries (femoropopliteal and infrapopliteal) for treatment of intermittent claudication or critical limb ischaemia (CLI). The literature search was last updated on 20 February 2021 without any restrictions on publication language, date, or status. Major amputations were analysed with time to event methods employing one and two stage models. Sensitivity and subgroup analyses, combinatorial meta-analysis, and a multivariable dose response meta-analysis to examine presence of a biological gradient were also performed. RESULTS: In all, 21 RCTs with 3 760 lower limbs were analysed (52% intermittent claudication and 48% CLI; median follow up two years). There were 87 major amputations of 2 216 limbs in the paclitaxel arms (4.0% crude risk) compared with 41 major amputations in 1 544 limbs in the control arms (2.7% crude risk). The risk of major amputation was significantly higher for paclitaxel coated balloons with a hazard ratio (HR) of 1.66 (95% CI 1.14 - 2.42; p = .008, one stage stratified Cox model). The prediction interval was 95% CI 1.10 - 2.46 (two stage model). The observed amputation risk was consistent for both femoropopliteal (p = .055) and infrapopliteal (p = .055) vessels. Number needed to harm was 35 for CLI. There was good evidence of a significant non-linear dose response relationship with accelerated risk per cumulative paclitaxel dose (chi square model p = .007). There was no evidence of publication bias (p = .80) and no significant statistical heterogeneity between studies (I2 = 0%, p = .77). Results were stable across sensitivity analyses (different models and subgroups based on anatomy and clinical indication and excluding unpublished trials). There were no influential single trials. Level of certainty in evidence was downrated from high to moderate because of sparse events in some studies. CONCLUSION: There appears to be heightened risk of major amputation after use of paclitaxel coated balloons in the peripheral arteries. Further investigations are warranted urgently.

来源:Eur J Vasc Endovasc Surg,查看原文。版权归原作者所有。

引用

  1. Katsanos K, Spiliopoulos S, Teichgräber U, et al. Editor's Choice - Risk of Major Amputation Following Application of Paclitaxel Coated Balloons in the Lower Limb Arteries: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. Eur J Vasc Endovasc Surg. 2021. PMID: 34326002. doi:10.1016/j.ejvs.2021.05.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。